Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The Atoh1 gene was first discovered in the Drosophila gene in 1998, and the variant of this gene was later found in almost all animal species genomes such as mice and humans. The Atoh1 gene is a functional gene that is transcribed into a 1065 bp long mRNA encoding a protein consisting of 354 amino acids, the transcription factor Atoh1, which is a member of the anterior neuron basic helix-loop-helix transcription factor family.
Atoh1 plays a role in the specificity of nerve cells in the central nervous system and peripheral nervous system and plays an important role in the development of secretory cells in the digestive tract. The study found that Atoh1 is a new anti-cancer gene. Closing this tumor suppressor gene can lead to cancer, and reopening this gene can help inhibit cancer. The Atoh1 gene controls the final step in cell differentiation, which ensures that the cell is positively defined without becoming a malignant cancer cell.
Figure 1. Summary of Atoh1 regulation. (Cheng, et al. 2017)
ATOH1 is a basic helix-loop-helix (BHLH) transcription factor that plays a key role in the development and regeneration of cochlear hair cells. ATOH1 is transcribed through a variety of signaling pathways, including Notch and Wnt signals. At the post-translational level, it is regulated by the ubiquitin-proteasome pathway. In vitro and in vivo studies have shown that manipulation of these signaling pathways not only controls development but also leads to regeneration of damaged cochlear hair cells. Recent advances in understanding the signaling networks involved in hair cell development and regeneration have led to the development of new strategies to replace lost hair cells.
Atoh1 and Brain Tumor
Sagal et al. studied the function of the neuronal transcription factor Atoh1 in neuronal differentiation of PSCs. It is shown that Atoh1 is induced during the neuronal transformation of human pluripotent stem cells (PSCs), and ectopic Atoh1 expression is sufficient to drive PSCs efficiently into neurons. The Atoh1 transcription factor plays a crucial role in the development of the cerebellum, and it is also implicated in certain other cancers in the brain, including medulloblastoma, the most common pediatric tumor in the nervous system. Studies have used a retroviral vector approach to eliminate the Atoh1 gene after birth. It was found that Atoh1 regulates the expression of the Gli2 gene and thus affects the so-called "Sonic Hedgehog" signaling pathway. This signaling pathway normally maintains the precursor cells of the cerebellum in an undifferentiated state. Accordingly, it is a delicate balance between cell proliferation and differentiation, this balance can lead to errors once tumor growth.
Atoh1 and Colon Cancer
The homolog Atoh1 gene in the Atonal gene group is associated with colon cancer. The main function of the Atoh1 gene is to regulate the final step of colonic epithelial cell differentiation. If this gene is lost or inactivated, it will cause colon cancer. Fukushima stabilizes Atoh1 protein by inactivating GSK-3β by Akt treatment with TNF-α, thereby producing carcinoma of colon and rectum (CRC) cell line. Atoh1 protein is also enriched in cancer stem cells, in which Lgr5 expression is up-regulated, cells are in the G0 / G1 cell cycle stage, resulting in chemical resistance to 5-fluorouracil and oxaliplatin and promoting cell migration. Immunofluorescence of human mucus colitis-associated colorectal cancer (CAC) specimens showed accumulation of NF-κBp65 in the nucleus and expression of Atoh1 in mucinous carcinoma. Kano et al. found that Atoh1 enhanced Wnt signaling, leading to the induction of Lgr5 as a representative stem cell marker with enrichment of cancer stem cells. In addition, a fluorescent ubiquitin-based cell cycle indicator system with delayed real-time imaging demonstrated cell cycle arrest in the G0 / G1 phase by Atoh1 protein stabilization. In conclusion, Atoh1 regulates the malignant potential rather than the differentiated phenotype of mucinous colon cancer (MC), suggesting that MC and signet ring cell carcinoma (SRCC) are more malignant than non-mucinous adenocarcinoma.
Atoh1 and Merkel Cell Carcinoma
Merkel cell carcinoma (MCC), also known as neuroendocrine cell carcinoma, is a low-grade malignant tumor that originates in the skin tactile body Merkel cells. Atoh1 may be an early indicator of carcinogenic mutations in tissues that direct cell differentiation. To validate this possibility in vivo, the researchers collected samples from 4 patients with MCC to investigate whether the Atoh1 gene has a down-regulation trend. Genomic DNA samples were detected by quantitative polymerase chain reaction. Expression analysis of MCC cell lines showed a negative correlation between Atoh1 levels and Merkel cell growth. The data support that Atho1 is an evolutionarily conserved tumor suppressor gene, and loss of Atoh1 promotes tumor formation and progression, and mutations occur at a higher frequency at the Atoh1 locus. Given the high deletion and methylation ratio of Atoh1, loss of Atoh1 function may be an early sign of the tumor.
Gambichler et al. successfully performed genomic DNA isolation and PCR amplification in 33 formalin-fixed paraffin-embedded tissues and three MCC cell lines, followed by Sanger sequencing of the entire ATOH1 gene to detect genomic aberrations. The research team determined the ATOH1 mRNA level by RT-PCR and immunohistochemical analysis of ATOH1 to quantify protein expression in tumor samples and cell lines, and found that genetic changes in MCC did not lose ATOH1 expression. However, protein expression of ATOH1 increased in late MCC, indicating that ATOH1 is involved in MCC progression.
Based on the above, Atoh1 is a useful diagnostic tool for the early detection and diagnosis of MCC. Similarly, treatment with MCC patients showed that Atoh1 epigenetic silencing is a powerful therapeutic approach with DNA methyltransferase inhibitors, as this restores Atoh1 expression and induces cancer cell death.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.